Viatris In-Depth Investment Research Report

Conclusion First

How facts, assumptions, inferences, and opinions are labeled

• Fact: Sourced from SEC filings, company investor-relations materials, official press releases, FDA, IQVIA, the U.S. Treasury, FRED, and live market data.

• Assumption: Maintenance capex, discount rate, long-term growth rate, liquidation discount, and similar inputs.

• Inference: Valuation, moat width, and long-term return ranges derived from facts and assumptions.

• Opinion: The final rating and the buy-or-not call.

Preliminary Conclusion

• Investment rating: Watch

• **Core judgment: **Viatris is a business that is understandable and cash-generative, but not high quality. Its strengths are global scale, a mature product portfolio, solid cash generation, and the clear deleveraging and relatively restrained capital returns of recent years. Its weaknesses are an industry that lacks pricing power, continuous natural erosion of the product base, recurring regulatory and manufacturing risk, and a balance sheet where intangibles and goodwill make up an outsized share, so "cheap on paper" does not mean "safe in assets." As of May 30, 2026, VTRS trades at roughly $16.26 with a market cap near $19.1 billion. On a free-cash-flow multiple it looks inexpensive, but from the vantage point of a long-term business owner, it does not currently offer a margin of safety wide enough.

• Does the current price offer a margin of safety: not obviously

• **Suitable investor type: **Better suited to contrarian value investors who can tolerate pharmaceutical regulation, falling product prices, and execution volatility; less suited to conservative long-term investors who put "wide moat, strong pricing power, durable high ROIC" first.

• **Greatest uncertainties: **

First, the pace at which the Indore plant's FDA warning letter / import alert is lifted, plus recovery progress after the Nashik fire; Second, the rate of natural erosion across the mature-branded and generic portfolio, and whether new products, complex formulations, and China growth can offset it; Third, whether management keeps channeling strong cash flow into high-return uses rather than low-quality M&A or "keep the scale" spending.

In One Sentence

If you treat Viatris as an acquisition target, it looks more like a global mature-drug platform with decent cash flow but no deep moat that needs constant repair, rather than a high-quality compounding machine that can easily run for 10-plus years.

Understanding the Business and the Industry Landscape

How this company actually makes money

Fact: Viatris is a global pharmaceutical company operating in 165+ countries and territories, with 30,000+ employees, 27 manufacturing/packaging/distribution sites, and 1,400+ approved molecules. The portfolio spans generics, complex formulations, well-known mature brands, and an expanding base of innovative assets, organized into four reporting segments: Developed Markets, Greater China, JANZ, and Emerging Markets. In 2025, net sales were $14.25 billion, of which branded drugs were $9.184 billion and generics were $5.066 billion. By region, Developed Markets accounted for $8.514 billion, Greater China for $2.333 billion, JANZ for $1.194 billion, and Emerging Markets for $2.210 billion.

Fact: The customers are not end patients but large purchasers within the pharmaceutical distribution chain and healthcare systems, including wholesalers, retail chains, hospitals, physicians, and pharmacies. The company discloses that its top three customers together represented about 25% of 2025 net sales, and on the receivables side, three customers made up about 24% of the accounts-receivable balance at the end of 2025. In the U.S., the customer base is broad but is effectively dominated by a handful of very large customers.

Fact: Revenue is fundamentally collected on a per-product-sale basis, with no software-style subscription model; revenue stability depends on the portfolio's lifecycle, regional tenders and reimbursement pricing, competitive entry, supply continuity, and channel bargaining. The company's top ten products together accounted for 36% of 2025 net sales, showing that while the portfolio is diversified, it still carries some product concentration.

Inference: This business is understandable, but not "simple" enough. You can see that it makes money selling drugs and that the cash flow comes from broad coverage of mature global products. But because the portfolio is sprawling, regional differences are large, the regulatory framework is complex, non-GAAP adjustments are numerous, and the history of M&A and divestitures is busy, it is not the kind of business where "one page of the financials lets you map out the next decade."

Business understandability score: 4/5.

Revenue stability, cost structure, and whether it is worth holding through a market closure

Fact: 2025 net sales fell versus 2024, with Developed Markets down 5%, JANZ down 11%, and Emerging Markets down 2%, while Greater China bucked the trend with 8% growth. The company disclosed that constant-currency revenue from the remaining business declined about 1% in 2025, of which roughly $370 million was tied to the Indore impact. Q1 2026 total revenue was $3.52 billion, up 8% year over year, with constant-currency net sales up about 3%; Greater China grew 22% year over year and Developed Markets grew 7%, though currency contributed a large part of that.

Fact: Within the cost structure, manufacturing, compliance, supply chain, and intangible amortization all weigh heavily. In 2025, total revenue was $14.2999 billion, cost was $9.2864 billion, and gross profit was $5.0135 billion, for a GAAP gross margin of about 35%, down sequentially from roughly 38% in 2024 and 42% in 2023. In Q1 2026, the company disclosed gross margin of only 33%, hit by $71.9 million in inventory and fixed-asset write-offs and manufacturing disruption from the Nashik fire.

Fact: The company has clear dependencies on a small set of customers, certain plants, third-party API and product suppliers, and the reimbursement tenders and price controls of various countries. It explicitly warns that some products' manufacturing processes are "highly precise and complex," that the number of its manufacturing facilities and third-party suppliers is limited, that markets such as Japan and Europe have government price cuts and tender systems, and that U.S. PBMs, buying alliances, and channel consolidation keep intensifying price pressure.

Inference: If the stock market closed for five years, I would be willing to hold this business at a lower price, but not willing to hold it at any price. The reason is not that it will disappear, but that it lacks the structural advantage that "gets better just by sitting there"; you have to keep tracking regulation, manufacturing, pricing, and the product mix rather than simply "sitting and waiting for the compounding."

Industry and competitive landscape

Fact: Industry demand is stable. The FDA notes that in the U.S., 9 of every 10 prescriptions are generics; IQVIA expects global drug volume to grow at about 1.9% CAGR over the next five years on a population-adjusted basis, indicating that total pharmaceutical demand is durable over the long run but is driven more by population and aging than by high-growth dynamics. U.S. net drug spending is still expected to grow through 2030, but innovative drugs and the GLP-1 class will absorb more of the profit pool, while mature drugs have weaker price elasticity.

Fact: Working against Viatris, this sub-industry itself faces long-term price compression. In its 10-K the company repeatedly notes that government price cuts, tenders, international reference pricing, PBM negotiation, and wholesale/retail consolidation all pull prices and margins down; for mature brands, once patent or exclusivity ends, both volume and price usually drop quickly.

Fact: Key comparables include Teva, Organon, Amneal, and some regional mature-drug or generic platforms. Teva delivered $17.258 billion in revenue and $5.305 billion in Adjusted EBITDA in 2025, with innovative brands AUSTEDO/AJOVY/UZEDY already serving as growth engines; Organon had $6.216 billion in revenue and $1.907 billion in Adjusted EBITDA in 2025; Amneal had $3.019 billion in revenue and $688 million in Adjusted EBITDA in 2025. Against these peers, Viatris is larger in scale but does not lead on growth quality.

Inference: This is not "a good company in a good industry"; it is more like a scale-based platform company in a mediocre industry. Stable demand keeps it from being too bad, but strong buyer power, poor pricing mechanisms, fierce competition, and ever-present regulatory risk make it hard to become a high-quality compounding asset.

Industry attractiveness score: 2/5.

Moat and Management

Moat assessment

Brand advantage Fact: The company does own several globally recognized mature brands, such as Lyrica, Lipitor, Creon, EpiPen, Wixela, Influvac, and Yupelri; management explicitly acknowledges that maintaining certain brands "typically confers a competitive advantage." But most of these brands are mature assets whose commercial value has largely passed its peak. **Verdict: **There is some, but it is mainly residual local brand value, not a company-wide strong-brand moat.

Cost advantage / scale advantage Fact: Viatris owns a global manufacturing and commercial platform, with 27 production/packaging/distribution sites, coverage across 165+ countries, and 1,400+ molecules, and the company believes it holds industry-leading capabilities in regulation, manufacturing, R&D, and supply chain. Although U.S. customers are concentrated, the company sees itself as advantaged in product breadth, supply chain, and R&D scale. **Verdict: **This is the company's most genuine source of moat. It is not consumer mindshare but the scale threshold of global manufacturing, registration, supply, distribution, and regulatory execution.

Network effects / data advantage / switching costs Fact: The company has no platform-style network effects; hospitals and channels can switch suppliers within compliance limits; most mature drugs are not high-switching-cost products. **Verdict: **Almost none.

Channel advantage Fact: The company relies on large distributors and retail chains, and those same customers also hold stronger bargaining power over price. **Verdict: **It has channel-coverage capability but not channel dominance; more "must depend on" than "can control."

Patents, licenses, regulatory barriers Fact: Some complex formulations, sterile/injectable products, and global registration and production qualifications do create entry barriers; but the company also makes clear that many products carry no strong patent protection or have limited patent life, and sales often fall quickly once protection is lost. **Verdict: **There are some barriers in complex formulations and global regulatory execution, but they are not broad or durable.

Corporate culture / operating capability Fact: In 2025 the board and management completed an enterprise-wide strategic review, setting out a strategy to "optimize structure, strengthen resource allocation, improve efficiency, and support reinvestment"; the proxy shows the company completed 60 regional business-development deals in 2025 and advanced projects such as selatogrel and cenerimod. At the same time, the company faced the Indore import alert and the Nashik fire over 2024-2026. **Verdict: **The culture looks more "operationally repair-oriented" than "excellence on offense." Management has done reasonably well on fixing the financials, cutting debt, and buying back stock, but manufacturing execution is not reassuring enough to earn a high score.

Capital allocation capability Fact: In 2024 the company repaid $3.7 billion of debt and reached its long-term gross-leverage target of 2.9x; in 2025 it repurchased $500.5 million and paid $561.2 million in dividends; across 2023-2025 it repurchased about $1 billion in total, retiring 94.2 million shares. The 2025 average repurchase price was about $9.3 per share, well below the current price. **Verdict: **Capital allocation over the past three years has been more rational than the market's impression, especially prioritizing debt reduction and buying back at low prices; but the large goodwill and intangibles left over from past M&A also show that the legacy system was not a top-tier capital allocator.

Overall Assessment Moat strength score: 2/5. Trend: stable, leaning narrower. The reason is that the real advantage lies in "the capabilities of a global mature-drug platform," not in "strong pricing power + high switching costs + exclusive assets." In mature drugs and generics, this kind of moat is hard to widen over time; it is more an operating threshold than an economic franchise.

Is management trustworthy, and is capital allocation rational

Fact: CEO Scott A. Smith has served as CEO since April 2023; the 2026 proxy shows he holds about 1.3293 million shares, and all directors and officers together hold about 3.2173 million shares, still under 1% overall. The company requires the CEO to hold 6x base salary in stock and tightened the rules further in 2025, no longer counting unvested PRSUs toward the ownership threshold.

Fact: In terms of disclosure style, management has not dodged problems. The company quantified Indore's impact on 2025 revenue, explained that the warning letter / import alert involved 11 products, stated that the Nashik fire caused $71.9 million in asset and inventory write-offs in Q1 2026, and gave a recovery timeline.

Fact: But capital allocation is not a perfect score either. The company recognized $2.937 billion of goodwill impairment in 2025, and also took a $2.94 billion goodwill impairment in Q1 2025 from interim impairment testing; this shows that historical M&A and asset pricing were not always prudent. In 2024, shareholders also approved increasing the share pool issuable under the 2020 incentive plan by another 49 million shares.

Inference: My read on the current management is "trustworthy, but not to be elevated to excellent." Over the past three years they have done better than the market stereotype on debt reduction, dividends, low-price buybacks, and structural cleanup; but the company still carries M&A legacy and operating incidents, and needs more years to prove itself.

Management and capital-allocation score: 3/5.

Financial Quality and Owner Earnings

Key financial quality

The table below organizes recent key figures on a verifiable basis. Because the company was formed in 2020 from the combination of Mylan and Upjohn and divested businesses multiple times from 2022 to 2025, the most analytically meaningful continuous basis is 2023-2025; 2021-2022 are better used to look at cash flow, debt, and share-count changes rather than mechanically comparing "growth rates."

**Note: **2022-2025 revenue, profit, cash flow, capex, cash, and debt come from the 2025 10-K and the 2023 10-K; free cash flow is estimated as "operating cash flow minus capex"; 2021 total revenue and year-end total debt were not directly re-verified against the original statements here, so they are left blank.

Fact: From 2023 to 2025, revenue declined sequentially from $15.427 billion to $14.300 billion; GAAP gross margin fell from about 41.7% to 38.2% and then to 35.1%; operating margin fell from about 5.0% to 0.1%, turning to -18.6% in 2025, mainly because of large goodwill impairments.

Fact: Despite an ugly income statement, operating cash flow has stayed resilient. From 2023 to 2025, operating cash flow was $2.80 billion, $2.30 billion, and $2.32 billion, with capex of about $377 million, $326 million, and $379 million, for free cash flow of about $2.42 billion, $1.98 billion, and $1.94 billion. In 2025, dividends were $561 million and buybacks were $501 million, so free cash flow amply covered shareholder returns.

Fact: The debt picture improved markedly. Year-end total debt was about $18.1 billion at the end of 2023, fell to about $14.0 billion in 2024, and ticked back up to about $14.4 billion in 2025 due to reclassification of short-term debt; in 2024 the company stated it repaid $3.7 billion of debt and reached its long-term gross-leverage target of 2.9x by year-end.

Fact: Share count fell modestly. Weighted-average shares dropped from 1.212 billion in 2022 to 1.171 billion in 2025; across 2023-2025 the company repurchased 21.2 million, 19.2 million, and 53.7 million shares respectively, totaling about 94.2 million shares and roughly $1 billion in cash.

Inference:

• **Profit quality: **GAAP profit quality is poor, badly distorted by intangible amortization, impairments, and fair-value swings; but cash profit quality is clearly better than accounting profit.

• **Growth quality: **This is not a "grow more, earn more" business; it is more a defensive platform that "relies on new products to offset erosion of old ones."

• **Accounting risk: **I see no "clear evidence of fraud," but I do see heavy non-GAAP adjustments, M&A legacy, an excessively high share of intangibles, and frequent goodwill impairments, which makes the statements hard to read and forces more reliance on cash flow than on EPS.

• **Cyclical resilience: **Drug demand is recession-resilient, but corporate profit is not resilient to regulation and execution incidents; 2025 is exactly a case of steady demand but very poor GAAP profit.

Owner Earnings estimate

Fact: 2025 net loss to parent was $3.515 billion. Major non-cash items that year included depreciation and amortization of $2.798 billion, goodwill impairment of $2.937 billion, and stock-based compensation of $178 million, plus other non-cash items of $969 million; but changes in operating assets and liabilities consumed cash net for the year, so operating cash flow was not artificially inflated. The company's 2025 operating cash flow was $2.316 billion.

Conservative estimation method

Rather than "adding and subtracting" up from net income to derive Owner Earnings, I use a more conservative approximation closer to Buffett's thinking:

Owner Earnings ≈ operating cash flow − maintenance capex

The reasons are: First, operating cash flow already reflects cash taxes, cash interest, and working-capital changes; Second, Viatris is a mature, manufacturing-heavy and compliance-intensive pharmaceutical platform, so maintenance capex should not be underestimated.

Assumption: Of 2025 total capex of $379 million, about 80%-90% is maintenance capex, corresponding to $300-340 million. This is a conservative assumption, because unlike asset-light software, this kind of business cannot treat most capex as optional growth capital.

On that basis:

• Conservative Owner Earnings ≈ 2.316 − 0.325 = $1.99 billion

• More conservative lower bound ≈ 2.316 − 0.340 = $1.98 billion

• Looser upper bound ≈ 2.316 − 0.300 = $2.02 billion

Inference: In the valuation I use $1.95-2.0 billion as the conservative starting point for current truly distributable cash flow. Against the current market cap of $19.1 billion, the equity implies a P/Owner Earnings of about 9.5x-9.8x; using free cash flow of $1.937 billion, the P/FCF is about 9.9x. This explains why the market sees it as "looking cheap," but also shows the market is discounting for structural decline, regulatory risk, and execution risk.

Intrinsic Value, Relative Valuation, and Margin of Safety

Current price and valuation starting point

As of May 30, 2026, VTRS trades at roughly $16.26, with a market cap of about $19.11 billion.

Fact: Per the year-end 2025 balance sheet, cash was $1.322 billion, total debt about $14.414 billion, net debt about $13.09 billion, and enterprise value about $32.2 billion.

Owner-earnings discounting

The table below uses an equity-perspective DCF, so the item being discounted is Owner Earnings rather than unlevered free cash flow. The discount rate is set at 9%-10%, my conservative required return for a company with a low moat, coexisting regulatory and execution risk, but relatively steady cash flow. The terminal growth rate is set at -1% to 1%.

**Note: **The above is the author's estimate based on 2025 operating cash flow and maintenance-capex assumptions, not company guidance; the core fragility is whether the mature portfolio keeps declining and whether the manufacturing/regulatory repair goes smoothly. Supporting data come from the 2025 10-K.

Inference: The current price of $16.26 sits roughly in the lower part of my neutral value range. That means it is not expensive, but also not cheap enough to compensate for the deficiency in business quality.

My range judgment is:

• Conservative intrinsic value range: $12-14.5/share

• Fair intrinsic value range: $16.5-18.5/share

• Optimistic intrinsic value range: $21-24/share

• Current price versus fair value: close to fair and slightly low, but not a deep discount

• **Required margin of safety: **for this kind of low-moat pharmaceutical platform, I want at least 25%-30%

• **Ideal buy-price range: **$11-13.5

• **Acceptable holding-price range: **$13.5-18

• **Clearly overvalued range: **$20-22 and above

Relative valuation

To keep this verifiable, the relative valuation below uses officially disclosed EBITDA / debt / cash and live market caps as much as possible. For Viatris, the denominator uses two approaches: First, 2025 free cash flow for an equity valuation; Second, 2024 official Adjusted EBITDA for an EV/EBITDA reference, since that figure is clearly captured in official materials.

**Note: **The market caps for Viatris, Teva, Organon, and Amneal come from live market data; debt/cash/EBITDA come from each company's official annual report or earnings release; EV/EBITDA is the author's estimate.

Inference: Viatris's relative valuation is not expensive, but not scarce either. It is not the single "cheapest and most stable in the industry" option. Teva is more expensive because the market gives more weight to its innovative assets and growth; Organon is cheaper because the market worries about its weaker base and heavier debt. Viatris sits between the two, consistent with its middling profile of "decent cash, average quality."

Asset value and liquidation value

Fact: At year-end 2025, total assets were $37.193 billion, of which intangibles were $15.102 billion and goodwill $6.755 billion, totaling about $21.857 billion; total equity was $14.711 billion. In other words, intangibles and goodwill combined far exceed book equity.

Inference: On a hard-asset view, Viatris has no strong asset cushion. A rough "tangible net worth" approach is:

Tangible equity ≈ total equity − intangibles − goodwill ≈ 14.71 − 15.10 − 6.75 ≈ -$7.1 billion

This does not mean the company will liquidate to zero; it means that what you hold is not a "cheap basket of assets," but a business whose value holds only if it keeps operating, keeps complying, and keeps selling drugs. So you cannot go long this name on "low P/B, high book value."

Margin-of-safety assessment

Answering the user's seven questions

• Is the current price cheap enough?

No. It is not expensive, but it has not reached a price at which I feel comfortable holding a thin-moat business.

• What is the most fragile assumption in the valuation? It is the assumption that "$1.9-2.0 billion of Owner Earnings can be sustained over the long run." If mature-product erosion, regulatory incidents, or channel price pressure intensify, this number will fall.

• If growth comes in below expectations, is there still a reasonable return? If cash flow merely holds flat or declines slightly, the return is likely still positive, but more like a 6%-8% "bond-like equity return" than an excellent equity return.

• If margins fall, does the investment still hold? As long as cash flow does not collapse meaningfully, the investment logic can still hold; but it would degrade from "undervalued" to "merely cheap."

• If the valuation multiple contracts, could it cause permanent loss? Yes. Because there is almost no hard-asset floor on the books, if the market compresses it from 9.5x Owner Earnings to 7x while cash flow also declines, the stock could fall back to single digits to the low teens.

• Is this a case of "good company, bad price"? My read on VTRS is the opposite: it is more like an average company at an average price.

• Is it worth waiting for a better price?

Yes. For a balanced, conservative 10-year investor, I would rather wait for $11-13.5, or wait for the company to prove over several consecutive quarters that "the repair is real, not one-off."

Margin-of-safety conclusion: insufficient.

Risks, the Bear Case, and Alternative Opportunities

The most important risks

Competition and price risk The mature-branded and generic industry Viatris operates in faces long-term price pressure. Government price cuts, tenders, and reference-pricing systems in Japan and Europe, plus PBM and channel concentration in the U.S., could keep compressing gross margin.

Regulatory and manufacturing risk The Indore plant received an FDA warning letter and import alert in 2024, affecting imports of 11 products into the U.S. and materially hitting 2025 financials; Nashik caught fire in February 2026, causing $71.9 million in write-offs and manufacturing disruption in Q1 2026.

Portfolio-erosion risk The top ten products account for 36% of net sales, and many mature brands and generics decline quickly once they lose exclusivity or face competition. The 2025 revenue declines across several regions already reflect this.

Asset-quality and accounting risk At year-end 2025, intangibles and goodwill combined exceeded $21.8 billion, and large goodwill impairments occurred in both 2025 and Q1 2025. Even absent fraud, this shows that historical M&A pricing and future cash-flow expectations carry wide elasticity.

Leverage and refinancing risk Although debt has fallen significantly from 2023, year-end 2025 total debt was still about $14.4 billion, so this is not a low-leverage company. The debt itself is manageable, but it amplifies any regulatory, manufacturing, or price shock.

The strongest bear case

The strongest bear argument runs roughly as follows:

"Viatris looks cheap only because it is a slowly declining, low-pricing-power, regulation-heavy, intangible-heavy mature-drug platform. Its high free cash flow is not because the business is excellent but because depreciation and amortization are large and reinvestment room is limited; once old products erode faster, the plants keep having incidents, or new products fail to take the baton, this 'high cash flow' will shrink year after year. At that point, the market's low multiple is reasonable, not a mistaken sell-off."

This is a powerful bear thesis. I see it not as an emotional short but as a sober read on the nature of this industry. The facts supporting this path include declining revenue, pricing pressure, manufacturing incidents, goodwill impairments, and the absence of a clear high-quality growth engine.

What facts would overturn the investment thesis

I would admit I was wrong, or at least would have to re-model, if the following occur:

• The Indore issue still cannot be resolved after 2026, with an expanding scope.

• Nashik recovery is slower than expected, with manufacturing disruption extending past the second half of 2026.

• The company's operating cash flow falls below $1.8 billion for two to three consecutive years, rather than holding around $2.0 billion.

• Greater China, new products, and complex formulations fail to offset mature-product erosion, leading to sustained low-to-mid single-digit constant-currency revenue declines.

• Management pivots to high-priced M&A rather than continuing to prioritize debt reduction, buybacks, or high-return reinvestment.

Comparison with other opportunities

Versus the strongest competitor Teva delivered $17.258 billion in revenue, $5.305 billion in Adjusted EBITDA, and $2.396 billion in free cash flow in 2025, and owns clear growth assets in AUSTEDO, AJOVY, and UZEDY, which is why it trades at a higher valuation. Part of Viatris's "cheapness" is precisely that it lacks growth engines of the same caliber. If you value business quality more, Teva may be the better company; if you value valuation more, Viatris is more attractive.

Versus a broad index The S&P 500 covers about 500 leading U.S. companies and roughly 80% of investable U.S. large-cap market value. For most long-term investors, a single stock is worth a slot only when it is clearly better than the index on quality or price. Viatris currently shows no such "clearly better than the index" advantage.

Versus risk-free yields / high-grade bonds As of the end of May 2026, the U.S. 10-year Treasury yield was roughly 4.4%-4.5%; FRED shows the Moody's Aaa corporate-bond yield in April 2026 at about 5.42%. Viatris's equity Owner Earnings yield is about 10%, on the surface well above bonds; but that extra yield is not free, it corresponds to business erosion, regulatory, execution, and asset-quality risk.

Concluding comparison

• Is buying it clearly better than buying the index? Not obviously.

• Is the expected return enough to compensate for the risk? For deep-value investors, barely worth discussing; for the balanced and conservative, not yet enough.

• Is it worth tying up my capital? It can be studied as a small contrarian-value position; as a core long-term compounding asset, it is not strong enough.

• If I could only hold 5 assets, does it qualify for the portfolio? For most conservative investors, no.

Checklist and Final Investment Conclusion

Investment checklist

**Note: **The above judgments are based on the preceding combined analysis of industry, cash flow, debt, asset quality, management, and execution risk.

Open questions and the limits of this report

• The company's full 2025 Adjusted EBITDA / ROIC / net debt-to-EBITDA on its own basis was not extracted item by item from the official filing HTML here, so the relative valuation leans more on the verified 2024 Adjusted EBITDA and 2025 free cash flow.

• 2021 revenue and year-end total debt were not directly re-verified here, so those columns in the historical table are explicitly left blank.

• The success probability and commercial peak of the innovative pipeline (selatogrel, cenerimod) still look more like options than the main pillar of the investment thesis at this stage.

Final investment conclusion

【Final Rating】 Watch

【One-sentence investment thesis】 Viatris is a global mature-drug platform with decent cash flow, an undemanding valuation, and capital allocation that has improved in recent years, but its moat is on the weaker side, asset quality is average, and execution and regulatory risk are on the higher side; the current price is not enough to offer a conservative 10-year investor a sufficient margin of safety.

【Core bull case】

• Operating and free cash flow remain strong, with 2023-2025 free cash flow holding roughly in the $1.9-2.4 billion range.

• Significant debt reduction over the past three years, plus ongoing buybacks and dividends, makes capital allocation fairly pragmatic.

• The scale threshold of the global manufacturing, registration, supply-chain, and distribution network is real.

• Greater China and some new products showed some growth resilience in 2025 and Q1 2026.

【Core bear case】

• The industry lacks pricing power, with government price cuts, tenders, PBMs, and channel consolidation continually pressing prices.

• Indore and Nashik show that manufacturing/compliance risk is not a low-probability event.

• The share of goodwill and intangibles is too high, and the large 2025 impairment shows asset quality is not solid.

• The revenue base is still being eroded by mature products, and a genuinely high-quality growth engine is not yet clear.

【Key assumptions】

• Owner Earnings can hold around $1.9-2.0 billion rather than sliding steadily below $1.6-1.7 billion.

• Indore is substantively resolved in 2026-2027, and Nashik recovery no longer drags on margins.

• Management keeps favoring debt reduction, low-price buybacks, and high-certainty investment over high-priced M&A.

【Fair buy price】 $11-13.5/share. Basis: a discount applied to the conservative-scenario intrinsic value of about $12-14.5, leaving a 25%-30% buffer for the thin moat and regulatory/execution risk.

【Target holding period】 If bought, it should be watched over 5-10 years, but only if you accept that it is not a "worry-free compounder" but a cash-flow value stock that needs continuous tracking.

【Expected annualized return】

• **Conservative scenario: **about 6%-8%

• **Neutral scenario: **about 9%-11%

• **Optimistic scenario: **about 12%-14%

These are the author's estimates based on the preceding DCF range and the current price, not company guidance.

【Maximum loss risk】 If manufacturing/regulatory problems drag on, mature products erode faster, and cash flow falls below $1.5-1.6 billion while the market compresses the valuation to about 7x Owner Earnings, a return to $7-10 is not impossible, implying a permanent capital-loss risk of about 40%-60% versus the current price. The key point supporting this pessimistic scenario is that the company has no solid tangible-asset floor.

【Tracking metrics】

• Constant-currency revenue growth, especially for the remaining business rather than consolidation-driven swings

• Net-sales changes in Developed Markets and Greater China

• New-product revenue and the contribution of complex formulations / the branded portfolio

• The gap between GAAP gross margin and adjusted gross margin

• Operating cash flow, free cash flow, and dividend coverage

• Debt-maturity profile and the trajectory of net debt

• Indore reinspection and warning-letter progress

• Nashik recovery pace and related one-off charges

• Average repurchase price and buyback amounts

• Milestones and return on invested capital for innovative assets such as selatogrel and cenerimod

【Signals that trigger reassessment】

• Constant-currency revenue in core markets clearly weakening for more than two consecutive quarters

• A trend-level step-down in operating cash flow

• Manufacturing or quality problems spreading to more core products

• Continued large impairments, indicating deteriorating asset quality

• Management beginning large, low-certainty M&A

• The stock rising above $20-22 without a matching improvement in fundamentals

【Final recommendation】 Put plainly, Viatris is worth studying, but not worth rushing to buy. It is neither a bad company nor clearly overvalued; the issue is that it looks more like "a cash-flow machine that needs continuous maintenance" than an excellent business with a wide moat that can easily cross a decade. For long-term value investors, the most rational stance is not to chase the price but to wait for a better price, or for clearer evidence of operational repair.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.